142 related articles for article (PubMed ID: 34157012)
21. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
22. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
24. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
[TBL] [Abstract][Full Text] [Related]
25. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
[TBL] [Abstract][Full Text] [Related]
26. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
27. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
[TBL] [Abstract][Full Text] [Related]
28. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
29. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
31. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract][Full Text] [Related]
33. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
34. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
35. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
37. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
38. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
40. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
